OSI

LAS VEGAS — Despite some recent setbacks, including ones in the RNAi field, oligonucleotide therapeutics are still likely to become the third major drug-development platform alongside small molecules and biologics in a matter of a few years, according to Art Krieg, the former CSO

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.

OSI will have access to AVEO's tumor models, archives, and biomarkers and will also acquire non-exclusive access to AVEO's proprietary bioinformatics platform.

OSI officials this week said that the availability of a long-vacant biocampus, the presence of a nearby budding biocluster, the promise of tax breaks and other economic incentives — and discontent with leaders in its current home base in New York's Long Island region — persuaded it to bypass North Carolina and Pennsylvania in favor of the Westchester County site.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.